Frontier Biotechnologies Inc.(Nanjing)


  • 2018-09-25  14:55:25

FB3001, a new transdermal patch, for treatment of musculoskeletal pain, is currently under clinical development. 

Through collaboration with ABsize, Phase II clinical trial for treating lower back pain has been completed in the United States. The clinical data demonstrates that FB3001 provides superior pain relief for patients with chronic lower back pain compared to placebo. FB3001 minimizes systemic drug exposure and side effects that are common with oral therapies. 

Frontier has filed an Investigational New Drug (IND) application for FB3001 in China and was granted approval by the National Medical Products Administration (NMPA) in March 2019. A Phase I bridging pharmacokinetic study has been completed.

Develop Innovative Therapies to Better Human Lives